Q3 2025 Baxter International Inc Earnings Call Transcript
Key Points
- Baxter International Inc (BAX) reported a 5% increase in global sales on a reported basis for the third quarter of 2025.
- The Healthcare Systems & Technologies segment demonstrated improved performance, with a 2% increase in sales.
- Advanced Surgery products saw strong demand, contributing to an 11% growth in sales globally.
- The company has launched Baxter GPS, a new growth and performance system aimed at driving continuous improvement.
- Baxter International Inc (BAX) is focusing on strengthening its balance sheet and plans to reduce its quarterly dividend to free up cash for deleveraging.
- The third quarter top line performance came in lower than previously issued guidance, with challenges in the Infusion Therapies and Technologies division and the Injectables and Anesthesia division.
- The Infusion Pump portfolio is under pressure due to a hold on deliveries and installations of the Novum IQ Large Volume pump, impacting sales.
- U.S. demand for IV solutions remains below pre-Hurricane Helene levels, with fluid conservation expected to continue into 2026.
- The Pharmaceuticals segment experienced softness in certain premix products, affecting growth.
- Baxter International Inc (BAX) has adjusted its full-year 2025 operational sales growth expectations down to 1% to 2%, reflecting evolving business dynamics.
Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcasted without Baxter's permission. If you have any objections, please disconnect at this time.
I would now like to turn the call over to Mr. Kevin Moran, Vice President, Investor Relations at Baxter International. Mr. Moran, you may begin.
Good morning, and welcome. Today, we'll discuss Baxter's third quarter 2025 results, along with an update to our full year 2025 outlook and newly issued fourth quarter 2025 guidance. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website. Joining me today are Andrew Hider, President, Chief Executive Officer; and Joel Grade, Executive Vice
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
